NCT05922878ClinicalTrials.gov
Study of ALTO-300 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder
In brief
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Phase 2325 participants sought75 sites1 country
Categories
Registered in 1 registry
- ClinicalTrials.govNCT05922878Open this record at ClinicalTrials.govSynced 3 weeks ago
One study can be registered in several registries. We show it once and link every record we hold.
Trial information is shown as published by the registry, in its original language.
Interested in this study?
Sign in or create an account to register your interest and follow this study.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2023-06-28; recorded start 2023-06-08
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Alto Neuroscience)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 45 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 325 participants (target), run at 75 sites.
How this score is built
- Enrolment24/40
321 participants (target)
- Site count19/25
45 sites
- Country count0/15
Single country
- Planned duration8/10
Planned over about 42 months
- Sponsor scale2/10
Alto Neuroscience has led 5 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Summary
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Conditions
- Major Depressive Disorder
Eligibility
| Sex | All |
|---|---|
| Ages | 18 Years – 70 Years |
| Healthy volunteers | No |
Eligibility as written in the registry
Eligibility in plain statements
This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.
Study design
| Study type | Interventional |
|---|---|
| Phase | Phase 2 |
| Allocation | Randomised |
| Intervention model | PARALLEL |
| Primary purpose | TREATMENT |
| Masking | QUADRUPLE (4) |
| Enrolment | 325 participants sought |
Sponsor and collaborators
- Alto Neuroscience Sponsor
Arms and interventions
- ALTO-300EXPERIMENTAL
Participants will receive ALTO-300 25mg capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).
- PlaceboPLACEBO_COMPARATOR
Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.
Interventions
- Drug ALTO-300
ALTO-300 capsule QD
- Drug Placebo
Placebo capsule QD
Outcome measures
Primary outcome
To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Ã…sberg Depression Rating Scale (MADRS).
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
Time frame Change over time for up to week 6
Secondary outcome
To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in all randomized participants as measured by the change over time up to week 6 in the Montgomery-Ã…sberg Depression Rating Scale (MADRS)
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
Time frame Change over time for up to week 6
Secondary outcome
To assess efficacy of adjunctive ALTO-300 versus placebo for MDD as measured by the change over time up to week 6 in response (>50% improvement from baseline) rates based on the MADRS
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
Time frame Change over time for up to week 6
Secondary outcome
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of the incidence, severity, and relatedness of Adverse Events.
Incidence, severity, and relatedness of Adverse Events
Time frame Assessed from Day 1 to Week 14
Secondary outcome
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Heart Rate.
Assessment of Heart Rate
Time frame Assessed from Day 1 to Week 14
Secondary outcome
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Weight.
Assessment of Weight Change
Time frame Assessed from Day 1 to Week 14
Secondary outcome
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Blood Pressure.
Assessment of Blood Pressure
Time frame Assessed from Day 1 to Week 14
Secondary outcome
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of suicidality with the Concise Health Risk Tracking Self-Report,12 item scale (CHRT-SR12).
The CHRT is a brief, self-report measure that systematically assesses both suicidal thinking and associated thoughts that may indicate the propensity for suicidal acts. The CHRT-SR12 is a 12 item scale. The patient assigns a score of 0-4 for each item of the scale, allowing for a total score of 0 to 48, with the higher score signifying more severe symptoms.
Time frame Assessed from Day 1 to Week 15
Dates
| Start date | June 8, 2023 (actual) |
|---|---|
| Primary completion | December 1, 2026 (estimated) |
| Completion | December 1, 2026 (estimated) |
| First posted | June 28, 2023 (actual) |
| Last updated | October 26, 2026 |
| Results posted | Not stated in the registry record |
| Status last verified | October 2026 |
Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.
Locations
30 sites are recruiting
United States
| Facility | City | State or region | Status |
|---|---|---|---|
| Site 114 | Albuquerque | New Mexico | Recruiting |
| Site 216 | Allentown | Pennsylvania | Terminated |
| Site 316 | Austin | Texas | Recruiting |
| Site 218 | Bellflower | California | Recruiting |
| Site 317 | Blackfoot | Idaho | Withdrawn |
| Site 236 | Boise | Idaho | Recruiting |
| Site 119 | Boise | Idaho | Active, not recruiting |
| Site 318 | Carlsbad | California | Active, not recruiting |
| Site 310 | Chicago | Illinois | Active, not recruiting |
| Site 202 | Cincinnati | Ohio | Recruiting |
| Site 159 | Clermont | Florida | Terminated |
| Site 207 | Clinton | Utah | Active, not recruiting |
| Site 203 | Colorado Springs | Colorado | Active, not recruiting |
| Site 239 | Conroe | Texas | Recruiting |
| Site 229 | Creve Couer | Missouri | Withdrawn |
| Site 102 | Dallas | Texas | Active, not recruiting |
| Site 343 | Denver | Colorado | Recruiting |
| Site 349 | Evergreen | Colorado | Active, not recruiting |
| Site 345 | Evergreen | Colorado | Active, not recruiting |
| Site 277 | Fairfax | Virginia | Recruiting |
| Site 238 | Fayetteville | Georgia | Recruiting |
| Site 148 | Fort Worth | Texas | Withdrawn |
| Site 347 | Fort Worth | Texas | Terminated |
| Site 217 | Glendale | California | Active, not recruiting |
| Site 279 | Hattiesburg | Mississippi | Withdrawn |
| Site 199 | Hickory | North Carolina | Active, not recruiting |
| Site 320 | Houston | Texas | Recruiting |
| Site 275 | Houston | Texas | Recruiting |
| Site 215 | Jackson | Mississippi | Active, not recruiting |
| Site 335 | Lafayette | California | Recruiting |
| Site 335 | Lafayette | California | Recruiting |
| Site 344 | Las Vegas | Nevada | Recruiting |
| Site 209 | Los Angeles | California | Active, not recruiting |
| Site 240 | Mankato | Minnesota | Recruiting |
| Site 201 | Marrero | Louisiana | Terminated |
| Site 219 | Mather | California | Recruiting |
| Site 350 | Media | Pennsylvania | Withdrawn |
| Site 225 | Miami Gardens | Florida | Active, not recruiting |
| Site 190 | Miami Lakes | Florida | Active, not recruiting |
| Site 265 | Minneapolis | Minnesota | Recruiting |
| Site 194 | Mission Viejo | California | Terminated |
| Site 206 | Missouri City | Texas | Withdrawn |
| Site 198 | Monroe | Louisiana | Terminated |
| Site 267 | Moorpark | California | Recruiting |
| Site 352 | Moosic | Pennsylvania | Active, not recruiting |
| Site 283 | New York | New York | Recruiting |
| Site 319 | New York | New York | Active, not recruiting |
| Site 214 | Norwalk | Connecticut | Withdrawn |
| Site 161 | Okeechobee | Florida | Active, not recruiting |
| Site 195 | Oklahoma City | Oklahoma | Terminated |
25 further sites are listed in the registry record.
Study documents
No documents are linked in this registry record.
Changes over time
- October 26, 2026
Enrolment target changed
Enrollment target revised up from 321 to 325
321325
- October 26, 2026
Site added
30 sites added (75 total)
4575